Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Virus Diseases × hepatitis C immune globulin, human × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Virus Diseases 1 Liver Cirrhosis 1 Hepatitis, Viral, Human 1 Hepatitis C 1 Carcinoma, Hepatocellular 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 2 hepatitis C immune globulin, human 1 Influenza Vaccines 1 Immunoglobulin G 1 Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01804829 2017-03-15

Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.

Biotest Pharmaceuticals Corporation

Phase 3 Completed

Gastrointestinal

Hepatitis, Viral, Human, Hepatitis C, Carcinoma, Hepatocellular, Liver Cirrhosis, Virus Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡